G8 Automated HPLC Analyzer: HLC-723G8-ST, 021560; and HLC-723G8-LA, 021674 Product Usage: The...
FDA Device Recall #Z-2745-2018 — Class II — June 6, 2018
Recall Summary
| Recall Number | Z-2745-2018 |
| Classification | Class II — Moderate risk |
| Date Initiated | June 6, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Tosoh Bioscience Inc |
| Location | Grove City, OH |
| Product Type | Devices |
| Quantity | 665 |
Product Description
G8 Automated HPLC Analyzer: HLC-723G8-ST, 021560; and HLC-723G8-LA, 021674 Product Usage: The Tosoh Automated Glycohemoglobin Analyzer HLC-723G8 is intended for in vitro diagnostic use for the quantitative measurement of % hemoglobin A1c (HbA1c) (DCCT/NGSP) and mmol/mol hemoglobin A1c (IFCC) in whole blood specimens. This test is to be used as an aid in diagnosis of diabetes and as an aid in identifying patients who may be at risk for developing diabetes.
Reason for Recall
HbAE is known to interfere with the HbA1c assay on the current version of software, Ver. 5.23. Customers should exercise caution when reviewing chromatograms and ensure that Flag 43 is enabled on their device to avoid reporting invalid test results in the presence of HbAE.
Distribution Pattern
Worldwide Distributed - US Nationwide. and the countries of Foreign distribution to Brazil, Caribbean, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Panama, Peru, and Uruguay.
Lot / Code Information
All active analyzers with Version 5.23 Software
Other Recalls from Tosoh Bioscience Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-2968-2020 | Class II | Tosoh Bioscience AIA-PACK BHCG Calibration Veri... | Aug 7, 2020 |
| Z-2967-2020 | Class II | Tosoh Bioscience AIA- PACK HCG Calibrator Set-I... | Aug 7, 2020 |
| Z-2423-2020 | Class II | AIA-900 Analyzer, Part no. 022930, UDI 04560189... | May 22, 2020 |
| Z-1420-2020 | Class II | AIA-360 Automated Immunoassay Analyzer, Product... | Jan 10, 2020 |
| Z-0675-2019 | Class II | ST AIA-PACK Homocysteine (HCY) is designed for ... | Nov 30, 2018 |
Frequently Asked Questions
A software recall means the device's embedded software or firmware has a defect that could affect its performance or safety. Many software recalls are corrected through firmware updates that can be applied without physically replacing the device. For implantable devices, the update may be delivered wirelessly during a routine clinic visit. For external devices, the manufacturer may provide updated software files or replacement units. Contact your healthcare provider to determine whether your specific device and software version are affected and what action is recommended.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.